[Funding News] ReSync Bio Raises Undisclosed Funding

ReSync Bio, a scientific software provider has secured an undisclosed amount in funding.

Caffeinated Capital, Atria Ventures, and angel investor Ramsey Homsany—co-founder of Octant Bio—were among the backers.

Read also – Flutterwave Partnership with MainStreet Bank

The money will be used by the company to finance important hiring and platform commercialization—the platform is currently accessible to businesses and academia.

“Our mission is to accelerate drug discovery programs across the industry,” said ReSync Founder and CEO Mihir Trivedi. “AI advances in generative drug discovery have transformed throughput on the digital side, but major challenges remain in translating this progress to the experimental side of the life sciences, where it takes far too long to go from idea to assay data. ReSync is a bridge that synergizes the digital and experimental worlds to help bring therapeutics to the clinic faster.”

Trivedi’s experience as an early engineer at PostEra, where he witnessed firsthand the need for more standard tooling in AI-driven drug development, served as the impetus for ReSync. The platform from ReSync is made to assist businesses in more effectively organizing and training their models, data, and experimental workflows.

“The reality in the lab today is that AI drug discovery programs are hindered by uncoordinated experiments and unstructured data,” said Chris Leiter of Atria Ventures. “ReSync is a universal tool that any life sciences company can use to eliminate preclinical bottlenecks and make their data work smarter. ReSync is the essential automation layer of the life sciences that makes AI bioacceleration possible.”

About ReSync Bio

A scientific software startup called ReSync Bio provides instruments to help biopharma businesses speed up their drug discovery processes.